Bovine Serum in Cell Culture

A basal medium such as DMEM or RPMI supplies salts, glucose, amino acids and vitamins. It does not supply the signals that tell a cell to grow, and for most primary and many established lines it is not sufficient on its own. Serum fills that gap with a complex, undefined mixture containing several thousand distinct proteins.

The functionally important contributions are:

• Growth factors and hormones -- insulin-like growth factors, PDGF, EGF, FGF, hydrocortisone, thyroid hormones and others -- which drive proliferation and survival.
• Attachment factors, principally fibronectin and vitronectin, which allow anchorage-dependent cells to adhere and spread on plastic.
• Transport proteins, especially albumin and transferrin. Albumin carries fatty acids, hormones and trace elements, and buffers against toxic compounds; transferrin delivers iron, which is both essential and toxic in free form.
• Lipids -- cholesterol, phospholipids and fatty acids -- that many cell lines cannot make in sufficient quantity.
• Protease inhibitors, notably alpha-1-antitrypsin and alpha-2-macroglobulin, which neutralise residual trypsin after subculture. This is why serum-containing medium is used to stop trypsinisation.
• Trace elements and antioxidants, including selenium.
• Physical protection, particularly in stirred or sparged culture, where serum proteins reduce shear and bubble damage.

The usual concentration is 10% (v/v) for routine work, though many established lines grow well at 5%, and some processes run at 2% or less. Reducing serum where a line tolerates it saves money, lowers the protein background in your samples, and reduces exposure to lot variation.

The defining property of serum is that it is undefined. Nobody, including the supplier, knows exactly what is in a given lot. That is simultaneously why it works so broadly and why it causes so much trouble.

Fetal bovine serum (FBS) and fetal calf serum (FCS) are the same product. The two names are used interchangeably, with FCS more common in Europe and FBS more common in North America. There is no difference in the material, and any supplier presenting them as distinct grades is not describing a real distinction. This is one of the most frequently asked questions about serum and the answer is genuinely that simple.

The bovine sera differ by the age of the animal, and that difference drives everything else:

Fetal bovine serum is collected from the fetus when a pregnant cow is slaughtered for food. Because the fetus is immunologically naive and developing rapidly, FBS is low in immunoglobulins and complement and rich in growth factors. That combination -- strong growth promotion with minimal interfering antibody -- is why it became the default and why it commands the highest price.

Newborn calf serum (NBCS) comes from calves under approximately 20 days old. It contains higher total protein and considerably more IgG than FBS, largely from colostrum, and fewer growth factors. It is markedly cheaper and works well for robust, undemanding lines.

Donor bovine serum is collected from animals of roughly 12-36 months maintained in a controlled, closed donor herd specifically for blood collection. The controlled herd gives better consistency and health documentation than abattoir-sourced material.

Adult bovine serum comes from mature cattle and has the highest immunoglobulin content and the lowest growth-promoting activity. It is the least expensive and suits only the most robust applications.

Choosing. Do not assume FBS is required. Many long-established lines were adapted to FBS historically and grow perfectly well on newborn calf serum, at a fraction of the cost and with less pressure on a strained supply chain. The correct approach is to test: run your line in parallel on FBS and a cheaper serum for several passages and measure growth rate, morphology and whatever functional endpoint matters. Where the cheaper serum performs equivalently, the change is free money. Where it does not, you now know why you are paying for FBS.

Geographic origin matters for regulatory rather than performance reasons. Australia and New Zealand carry the strongest transmissible spongiform encephalopathy country-status and their serum is priced accordingly; United States and South American origins are widely used. Where origin matters to your application it must be documented on the certificate of analysis, not assumed.

Sterile filtration. Serum is filtered through successive membranes down to 0.1 um, usually in triplicate, to remove bacteria and mycoplasma. A 0.1 um rating rather than the usual 0.2 um is used specifically because mycoplasma can pass a 0.2 um filter.

Heat inactivation: 56 C for 30 minutes. This is the standard condition, and its purpose is narrow -- to destroy complement activity while leaving growth-promoting properties substantially intact. Complement is a cascade of serum proteins that can lyse cells when activated by antibodies, which matters in immunological assays.

Heat inactivation is applied far more widely than it needs to be, largely by habit inherited from older protocols. It is genuinely necessary for complement-sensitive work: immunological and cytotoxicity assays involving antibodies, complement-mediated lysis studies, and some primary immune cell cultures. It is usually unnecessary for routine culture of established lines, and it is not free -- heating degrades some growth factors, and heat-inactivated serum reliably produces more precipitate and flocculent material. If you are heat-inactivating because the protocol you inherited said so, it is worth testing whether it makes any difference to your cells. Many labs find it does not. Note also that heat inactivation is not a sterilisation or virus-clearance step; it does not substitute for filtration or irradiation.

Gamma irradiation is applied to reduce the risk of adventitious agents, with validated processes typically in the 25-45 kGy range and reported reductions of 6-8 logs for common bovine viruses and mycoplasma. It is performed on frozen serum to limit damage to proteins. Irradiated serum is standard for applications with a formal viral safety requirement and is increasingly used generally. Some growth-factor loss occurs, so an irradiated lot should be performance-tested like any other rather than assumed equivalent to its non-irradiated counterpart.

Precipitate is normal. Flocculent material or fine particles appearing in thawed serum are almost always cryoprecipitated fibrin and lipoprotein, not contamination. They are harmless and can be ignored or removed by settling; do not filter serum yourself to remove them, since this strips proteins and risks contaminating a sterile product. Heat-inactivated serum precipitates more heavily than untreated serum.

Serum varies between lots. Two lots from the same supplier, the same origin and the same grade can support noticeably different growth rates, plating efficiencies and differentiation behaviour. For a sensitive cell line or a long study, this variation is a real threat to reproducibility -- a change of serum lot mid-project can shift results in ways that are very hard to diagnose afterwards.

Lot testing procedure:

1. Request samples. Ask the supplier for 25-50 mL test samples of three to five current lots, along with the certificate of analysis for each.
2. Test in parallel against your current lot as a reference, using your own cells, your own medium and your own assays. Supplier data cannot substitute for this, because it was generated on different cells.
3. Measure what matters to you. At minimum: growth rate over several passages, plating or cloning efficiency, and final viable density. Add the functional endpoint your work depends on -- differentiation, transfection efficiency, virus yield, antibody titre, morphology. A lot that supports fast growth but blocks differentiation is a bad lot for a differentiation lab.
4. Run enough passages. Single-passage tests miss cumulative effects. Three to five passages is a reasonable minimum.
5. Reserve the winning lot. Suppliers will hold a reserved quantity for a defined period. Reserve enough for the project or, ideally, for a year of work.
6. Overlap when transitioning. When a reserved lot runs out, test the replacement in parallel against the old one before switching, rather than switching and hoping.

Certificate of analysis. Review it rather than filing it. Useful entries include endotoxin (commonly specified below 10 EU/mL, with low-endotoxin grades below 1 EU/mL), haemoglobin as an indicator of haemolysis during collection, total protein, osmolality, pH, sterility and mycoplasma testing, viral testing, and country of origin.

Traceability. The International Serum Industry Association operates a traceability certification programme intended to document the chain from abattoir to end user through independent third-party audit. This matters because serum mislabelling and adulteration -- product sold as a higher grade or a more favourable origin than it actually is -- has been a documented problem in this market, driven by large price differentials between origins. Buy from suppliers who can document origin and chain of custody, and treat an unusually cheap lot of premium-origin serum with suspicion.

Storage and handling. Store at -20 C. Thaw at 2-8 C overnight, or at room temperature or 37 C with periodic gentle swirling; do not leave serum sitting at 37 C for extended periods and do not thaw at higher temperatures. Aliquot on first thaw into single-use volumes, because repeated freeze-thaw degrades serum and generates precipitate. Protect from prolonged light exposure, which degrades riboflavin and some other components.

Where fetal bovine serum comes from. FBS is a by-product of the beef industry. It is not produced by farming animals for serum. When a cow that turns out to be pregnant is slaughtered for meat, the uterus and fetus are removed at the abattoir, and blood is collected from the fetus, which is then processed into serum: clotted, centrifuged, filtered and frozen. Country of origin refers to where that collection took place. This section answers the sourcing question directly, because researchers ask it and a supplier page that avoids it is not a useful reference.

The collection procedure. Fetal bovine serum is a by-product of the beef industry. When a cow that turns out to be pregnant is slaughtered, the fetus is removed and blood is collected by cardiac puncture from the unanaesthetised fetus. The core welfare question is whether the fetus is capable of experiencing the procedure. The scientific position is not settled, and it turns on the stage of development and on whether the fetus remains unconscious after separation from the maternal circulation. Bodies including the NC3Rs have noted that the process is not comprehensively regulated -- the EU Directive 2010/63/EU on the protection of animals used for scientific purposes does not clearly cover fetal collection -- and that there is limited evidence that existing guidelines are protecting the animals in practice. Reasonable scientists hold different views on the severity of the concern, but it is not a manufactured controversy and it is not resolved.

The reproducibility argument is independent of the ethics, and for many labs it is more immediately persuasive. Serum is undefined and variable. Different lots contain different concentrations of hundreds of bioactive molecules. Historical records show this was recognised very early -- Puck observed that toxic factors appear in serum to varying degrees, that every batch must be tested, and that serum collected in some seasons had to be discarded at high rates. If any given batch can change how cells behave, then serum is an uncontrolled variable sitting in the middle of essentially every experiment, and one that cannot be reported in a methods section in any meaningful way. "10% FBS" describes almost nothing.

Supply and price. FBS supply is tied to beef slaughter volumes and to the incidence of pregnancy at slaughter, neither of which responds to demand from the life sciences. The market has experienced repeated price spikes and shortages. For a process being scaled toward manufacture, this is a genuine business risk, not merely an inconvenience.

Regulatory direction. Regulators and funders increasingly expect animal-origin-free raw materials in biologics and cell therapy manufacturing, both to remove adventitious agent risk and to improve process control. A research process built on serum will eventually have to be re-developed without it if it moves toward the clinic, and doing that late is considerably more expensive than doing it early.

Alternatives, honestly assessed.

• Chemically defined and serum-free media are the strongest option where they exist for your cell type. CHO, HEK293, hybridoma, insect, and many other workhorse lines have excellent commercial serum-free and animal-origin-free media, and in bioprocess settings these routinely outperform serum-containing medium on yield, consistency and downstream purification. For these cells the argument for serum is essentially finished.
• Defined supplements -- recombinant human albumin, recombinant insulin, recombinant transferrin, ITS mixtures, chemically defined lipids -- reconstruct serum's key functions from known components. This is how most serum-free formulations are built.
• Human platelet lysate (hPL) is a well-established substitute for FBS in mesenchymal stromal cell culture, often supporting faster expansion than FBS. It is human-derived rather than fully defined, so it exchanges one variable material for another, but it removes the bovine ethical and safety issues and is used clinically.
• Serum reduction is an underused intermediate step. Many lines tolerate 5% or 2% with no measurable penalty. This is available immediately, requires no adaptation work, and reduces cost and variability today.

The honest limitation. Serum-free alternatives do not exist for every cell type, and adaptation takes time and can fail. Some primary cells and some poorly characterised lines still genuinely require serum, and pretending otherwise helps nobody. The defensible position is not that serum must never be used, but that it should be a deliberate choice for cells that need it rather than a default applied to cells that do not -- and that any line being carried forward into scaled or clinical work should be moved off serum as early as is practical.

Adaptation is usually straightforward for suspension-adapted production lines and harder for adherent primary cells.

Sequential adaptation is the standard, lower-risk approach. Reduce serum stepwise across passages -- for example 10%, 5%, 2.5%, 1%, 0.5%, 0% -- allowing the culture to return to its normal doubling time and to above 90% viability before each further reduction. Expect the process to take several weeks. Do not proceed to the next step while the culture is still struggling.

Direct adaptation -- switching straight into serum-free medium -- is faster and sometimes works, particularly for robust suspension lines in a well-matched commercial medium. Keep a serum-containing backup culture running in parallel, because the failure mode is losing the culture.

Practical points:

• Bank cells before and after. Freeze vials at the starting point in case adaptation fails, and bank the adapted line immediately once it is stable. Losing a successfully adapted line is a painful and avoidable mistake.
• Expect a slower growth phase. A transient drop in growth rate during adaptation is normal; a sustained one means the step was too large.
• Attachment may change. Adherent cells losing serum lose fibronectin and vitronectin, so they may need a coated surface -- recombinant vitronectin, laminin or a defined attachment matrix -- rather than bare plastic.
• Trypsinisation needs rethinking. Without serum there are no protease inhibitors to neutralise trypsin, so use a defined trypsin inhibitor or a recombinant dissociation reagent, and do not rely on dilution alone.
• Shear protection matters more. Serum-free suspension cultures usually need a surfactant such as poloxamer 188 to protect against sparging and agitation damage. Most commercial serum-free media include one; check before assuming.
• Re-validate your assays. Removing serum changes protein background, changes free versus bound concentrations of anything you add, and can change apparent potency in a dose-response assay. Do not compare serum-free results directly against historical serum-containing data without checking.

Serum-containing, serum-free, animal-origin-free and chemically defined -- the terms are not interchangeable. They are frequently used loosely, and the distinctions matter when specifying a process:

The practical hierarchy runs serum-containing, then serum-free, then animal-origin-free, then chemically defined, with each step giving more control and usually costing more. A medium can be serum-free and still contain bovine albumin, and an animal-origin-free medium can still contain an undefined plant hydrolysate -- both are common sources of confusion when specifying a process. See the chemically defined medium reference for a fuller treatment of defined formulations.